Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Irritable Bowel Drugs From Salix, Actavis Await FDA Action In 2015

This article was originally published in The Pink Sheet Daily

Executive Summary

With new retreatment data in hand, Salix is again pursuing a supplemental claim for the antibacterial Xifaxan, while Actavis is seeking approval of eluxadoline, a new molecular entity with dual opioid receptor activity.

You may also be interested in...



Actavis Flexes Its Commercial Muscles Ahead Of Allergan Integration

Before adding Allergan into the mix – and taking on its name – Actavis wants to show investors that it has a solid foundation as a growth pharma with strong brands in GI, CNS and women’s health.

Valeant Reasons, Ackman Threatens In Latest Allergan Takeover Moves

Valeant and activist investing partner Bill Ackman took opposite approaches to reports that Allergan may be pursuing Salix buyout as a defensive move to block a takeover. Acquiring Salix could put the cost of Allergan out of Valeant and Ackamn’s reach.

Valeant Reasons, Ackman Threatens In Latest Allergan Takeover Moves

Valeant and activist investing partner Bill Ackman took opposite approaches to reports that Allergan may be pursuing Salix buyout as a defensive move to block a takeover. Acquiring Salix could put the cost of Allergan out of Valeant and Ackamn’s reach.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS077686

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel